Beyond the Skin: Uncovering Systemic Mastocytosis (SM) in Dermatology Practice is organized by i3 Health.
Dates Available:
February 12, 2026 - February 11, 2027
Statement of Need:
Systemic mastocytosis (SM) is a rare disease characterized by the increase and accumulation of clonal mast cells in the skin or in various extracutaneous organs. The diagnosis of SM is challenging. Patients may present with symptoms including itching, flushing, maculopapular mastocytosis lesions, abdominal pain, diarrhea, cognitive dysfunction, weight loss, fatigue, depression, mood changes, musculoskeletal pain, and osteoporosis. It often takes months to years for patients to receive a correct diagnosis. Recognition of maculopapular cutaneous mastocytosis lesions and investigation of other signs and symptoms that could indicate SM can lead to earlier diagnosis, referral, and appropriate treatment for patients. Therefore, it is crucial to take a multidisciplinary approach—involving dermatologists, oncologists, allergists, and other healthcare professionals—to optimize the diagnosis, workup, treatment, and management of SM (Ustun et al, 2025). In this activity, Lauren M. Madigan, MD, Associate Professor in the Department of Dermatology, University of Utah, will explore strategies for uncovering SM in dermatology practice.
Learning Objectives:
Upon completion of this activity, participants should be able to:
DISCLOSURE OF RELEVANT FINANCIAL INFORMATION WITH INELIGIBLE COMPANIES
i3 Health endorses the standards of the ACCME that require everyone in a position to control the content of a CME activity to disclose all financial relationships with ineligible companies that are related to the content of the CME activity. CME activities must be balanced, independent of commercial bias, and promote improvements or quality in health care. All recommendations involving clinical medicine must be based on evidence accepted within the medical profession.
A conflict of interest is created when an individual has an opportunity to affect CME content about products or services of an ineligible company with which he/she has a financial relationship, which therefore may bias their opinions and teaching. This may include receiving a salary, royalty, intellectual property rights, consulting fee, honoraria, stocks, or other financial benefits.
i3 Health will identify, review, and mitigate all relevant financial relationships that speakers, authors, or planners disclose prior to an educational activity being delivered to learners. Disclosure of a relationship is not intended to suggest or condone bias in any presentation but is made to provide participants with information that might be of potential importance to their evaluation of a presentation. i3 Health does not endorse any products or services.
Relevant financial relationships exist between the following individuals and ineligible companies:
The i3 Health planners, reviewers, and managers have nothing to disclose.
Lauren M. Madigan, MD, discloses that she has served on an advisory board or panel for Blueprint Medicines and that she has served on a speaker's bureau for Blueprint Medicines.
i3 Health has mitigated all relevant financial relationships.
INSTRUCTIONS TO RECEIVE CREDIT
In order to receive credit for this activity, participants must submit a completed evaluation at the end of the activity.
COMMERCIAL SUPPORT
This activity is supported by a medical education grant from Blueprint Medicines.
Aggregate participant data will be shared with commercial supporters of this activity.
CONTACT INFORMATION
Technical queries or questions regarding activity credit should be directed to i3 Health at support@emedevents.com.
The information provided at this CME activity is for continuing education purposes only and is not meant to substitute for the independent medical/clinical judgment of a healthcare provider relative to diagnostic and treatment options of a specific patient’s medical condition.